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Recent insights into the function and regulation of the bile salt
export pump (ABCB11)
Abstract
PURPOSE OF REVIEW: Generation of bile is an important function of the liver. Its impairment can be
caused by inherited mutations or by acquired factors and leads to cholestasis. Bile salts are an important
constituent of bile and are secreted by the bile salt export pump (BSEP) from hepatocytes. RECENT
FINDINGS: Significant progress was made in the understanding of mechanisms and consequences of
malfunctioning BSEP. This information was gained from extensive characterization of patients with
inherited BSEP deficiency and the subsequent characterization of the identified mutations in
heterologous expression systems. Furthermore and importantly, clinical evidence shows that patients
with severe BSEP deficiency are at risk to develop hepatocellular carcinoma. Bile salts are now
recognized to be important in the modulation of whole body energy homeostasis. Because BSEP is the
rate-limiting step in hepatocellular bile salt transport, it controls the spill over of bile salts into the
systemic circulation. Therefore, an indirect role of BSEP in energy homeostasis becomes more and more
likely. SUMMARY: In summary, knowledge on the physiologic and pathophysiologic role of BSEP is
rapidly progressing. It can be anticipated that the next major step in better understanding BSEP should
come from information on structure-function relationship. However, given the difficulty in structure
determination of mammalian transporters, this will require major efforts.
Recent insights into the function and regulation of the bile salt 




Division of Clinical Pharmacology and Toxicology, Department of Medicine, University 





Department of Medicine 








key word: liver, bile formation, cholestasis, inherited disease, polymorphisms 
 
 
Footnote: BST is supported by grant # 3100AO112524/1 
Abstract 
Purpose: Generation of bile is an important function of the liver. Its impairment can be 
caused by inherited mutations or by acquired factors, which leads cholestasis. Bile salts are an 
important constituent of bile and are secreted by the bile salt export pump (also known as 
ABCB11) from hepatocytes. 
Recent findings: Significant progress was made in the understanding of mechanisms and 
consequences of malfunctioning BSEP. This information was gained from extensive 
characterization of patients with inherited BSEP deficiency and the subsequent 
characterization of the identified mutations in heterologous expression systems. Furthermore 
and importantly, clinical evidence shows that patients with severe BSEP deficiency are at risk 
to develop hepatocellular carcinoma. Bile salts are now recognized to be important in the 
modulation of whole body energy homeostasis. Since BSEP is the rate limiting step in 
hepatocellular bile salt transport, it controls the spill over of bile salts into the systemic 
circulation. Thus, it becomes more and more likely that BSEP plays an indirect role in energy 
homeostasis. 
Summary: In summary, knowledge on the physiological and pathophysiological roles of 
BSEP is rapidly progressing. It can be anticipated that the next major step in better 
understanding BSEP will come from information on structure-function relationships. Given 




In the small intestine, bile is indispensable for the absorption of lipids, which are an essential 
dietary energy source. Hence, ongoing and undisturbed bile flow into the gut is vital for 
mammals to meet their energy needs. Bile is produced by the liver and consists of 
phospholipids and bile salts forming mixed micelles. These mixed micelles are acceptors for 
poorly water soluble substances. Hence, the bile fluid not only mediates absorption of lipids 
from the gut, but also provides a vehicle for the disposal of poorly water soluble waste 
products. 
 
Bile salts constitute a major portion of bile and are secreted by hepatocytes into the canaliculi. 
From there, they flow with other bile constituents into the gall bladder, except in species that 
are devoid of it. The gall bladder is a concentration and storage device for bile salts and other 
bile constituents (1). Thereafter, bile salts enter the duodenum, where they assist in the 
absorption of lipids and fat soluble vitamins. In the intestine, bile salts are absorbed both 
passively and actively and are transported back to the liver via the portal circulation. There, 
bile salts are taken up from the sinusoidal blood plasma by hepatocytes, where their journey 
starts again. This process of bile salt circling through the gut to the liver is known as 
enterohepatic circulation (1-4). 
 
Bile salt secretion by hepatocytes requires the coordinate action of distinc hepatocellular 
transporters located in the sinusoidal and in the canalicular membrane of hepatocytes (5-7). In 
the sinusoidal hepatocyte membrane, uptake of bile salts occurs predominantly in a sodium-
dependent manner via the sodium-taurocholate cotransporting polypeptide and to a minor 
extent in a sodium-independent manner mediated by organic anion transporting polypeptides 
(5, 6). Bile salt secretion across the canalicular membrane is known to be the rate limiting step 
of hepatocellular bile salt secretion and is mediated by an ATP-binding cassette (ABC) 
transporter named bile salt export pump Bsep (in rodents, BSEP in humans) or 
Abcb11/ABCB11 (5-8). Hence, due to its strategic location, BSEP drives and maintains 
enterohepatic circulation of bile salts. 
 
BSEP in liver disease 
The key role of BSEP in hepatocellular bile salt handling becomes evident in patients with 
genes leading to defective BSEP function, who develop severe liver disease with progressive 
familial intrahepatic cholestasis type 2 (PFIC2) (9). A milder variant of this disease often 
comes with recurring episodes of cholestasis and is called benign recurrent intrahepatic 
cholestasis. A group of these latter patients also has mutations in the BSEP gene (10). 
Together, mutations in the BSEP gene represent a continuum between mild to severe, 
progressive forms of intrahepatic cholestasis and lead to BSEP deficiency syndrome (11, 12). 
Frequent mutations in the BSEP gene can be grouped into missense mutations, nonsense 
mutations, deletions, insertions and splice site mutations. A recent exhaustive study 
performed in 109 families of patients with severe BSEP deficiency syndrome not only 
analysed BSEP genes for mutations but also investigated BSEP expression by 
immunohistochemistry in biopsies. The vast majority of patients had abnormal or absent 
BSEP staining - the latter predominating (13). Hence, mutations in the BSEP gene lead 
frequently to absent BSEP. Even though no large studies on mRNA levels in patients with 
BSEP deficiency syndrome are available, quality control in the endoplasmic reticulum 
probably leads to degradation of truncated and wrongly folded BSEP proteins. This study (13) 
also revealed that the common E297G and D482G mutant forms of BSEP varied most in their 
expression level between patients. This is of interest, as E297G and D482G have been shown 
to display residual (14) and normal (15) transport activity, respectively. In an elegant 
extension of the histologic characterization of patients with bile salt deficiency syndrome, the 
impact of mutations and single-nucleotide polymorphisms in the BSEP gene on the effect of 
pre-mRNA splicing and processing of BSEP protein was investigated (16). The authors 
identified 20 mutations/SNPs with reduced wild-type splicing and consequently reduced 
levels of normal mRNA in vitro. The majority of the mutants expressed in CHO-K1 cells led 
to protein retention in the endoplasmic reticulum and subsequent degradation. Of note, the 
mutant D482G, which is common in Europe displayed enhancement of aberrant splicing. This 
provides a possible explanation for the wide variation of BSEP expression found in patients 
with D482G mutations leading to clinical phenotypes with variable severity. 
 
Missing or non-functional BSEP lead to accumulation of bile salts within hepatocytes. 
Clinical observations from patients with severe forms of BSEP deficiency syndrome have 
revealed that these patients, who are often very young, are at significant risk to develop 
hepatocellular carcinoma (13, 17). How elevated intracellular bile salts are transforming cells 
is not yet known to detail, but it is likely that bile acid induced carcinogenesis involves 
mitochondria as bile salts are toxic to mitochondria (18, 19). Furthermore, bile salts may 
interact with signalling cascades  controlling cell cycle (20) and/or activate homeobox genes 
(21) and thereby ultimately transform cells. It is also conceivable that elevated intracellular 
bile salt levels may interfere with DNA repair mechanisms. And finally, bile salts have been 
shown to lead to a reversible induction of differentiation and cell polarization of rat hepatoma 
cells, again indicating pleiotropic action of intracellular bile salts (22). 
 
Inhibition of BSEP by endogenous metabolites such as for example aberrant bile salts (23) or 
drugs (24-27) leads to acquired BSEP deficiency syndrome (intrahepatic cholestasis). Drug 
induced cholestasis constitutes a clinically important and often severe problem (28). As the 
risk for such events is rare (e.g. 8.5 per 100,000 in the first 45 days for first time users of 
flucloxacillin (29)), it is evident that patients suffering from adverse drug reactions my carry 
susceptibility factors. To date, c.1331T>C (p.V444A) in exon 13 and c.2029A>G (p.M677V) 
in exon 17 of the BSEP gene are two nonsynomous SNPs, which have consistently been 
observed with frequences of higher than 0.5 % (8, 30-32) in different cohorts. A study of 
hepatic protein expression levels of four canalicular ABC transporters revealed a large 
interindividual variability for all the investigated transporters (BSEP, MDR1, MDR3, MRP2) 
(33). Interestingly, individuals carrying the p.V444A variant tended towards lower BSEP 
expression levels and all of the 17 % of the 110 individuals having low or very low BSEP 
expression levels were carrying at least one c.1331T>C allele. Functional characterization of 
these two BSEP variants Sf9 cells revealed no difference in their kinetic properties (34). 
 
Individuals carrying the p.V444A variant could be at a higher risk for developing acquired 
BSEP deficiency syndromes. This hypothesis is supported by findings in patients with drug 
induced cholestasis (34) and in patients with intrahepatic cholestasis of pregnancy (35, 36), 
where the c.1331T>C variant of BSEP is significantly more frequent than in controls. These 
three studies therefore identified the c.1331T>C variant of BSEP as a susceptibility factor for 
acquired BSEP deficiency syndrome. It should be noted that a study in a Swedish cohort with 
intrahepatic cholestasis of pregnancy did not show a difference in the distribution of common 
BSEP haplotypes (37). This discrepancy could in part relate to the fact that the latter study 
investigated haplotypes, while the other studies investigated frequencies of frequent SNPs. In 
three case reports (2 patients with cholestasis of pregnancy and one patient with benign 
recurrent intrahepatic cholestasis type 2), homozygocity for 444A was observed once and 
heterozygocity for 444A was observed twice (38-40). Clearly, while the association of a 
common BSEP variant with increased risk for acquired BSEP deficiency syndromes is 
interesting, independent studies with large cohorts are needed to strengthens this concept. 
 
A patient with benign recurrent BSEP deficiency syndrome associated with compound 
heterocygosity of two BSEP mutations with transport activity in Sf9 cells (14). The challenge 
will be to obtain information on minimal canalicular BSEP levels needed for proper bile salt 
secretion. BSEP is indirectly also important for systemic bile salt concentrations, as impaired 
BSEP function will lead to a spill-over of bile salts into the systemic circulation. In a study 
involving a large number (>5000) individuals aimed at the identification of genetic variants 
regulating fasting glucose levels, an SNP located in the vicinity of the BSEP gene was found 
to positively correlate with fasting glucose levels (41). It is interesting to note that the same 
study identified two additional SNPs in intron 19 of the BSEP gene, which also strongly 
associate with fasting glucose levels. A direct role or modulation via transcription factors of 
bile salts to body energy homeostasis is rapidly evolving (42-46). BSEP activity may hence 
have indirectly far reaching systemic effects on energy homeostasis. 
 
Taken together, there is now overwhelming evidence from patients with liver diseases 
illustrating the key role of BSEP in canalicular bile formation and progress in understanding 
the pathophysiologic consequences of molecular defects and/or variants of BSEP is rapidly 
evolving. 
 
Lessons learned from in vitro studies of BSEP mutations 
While undoubtedly a lot has been learned from patients, such studies lack mechanistic 
information on the influence of changes in the BSEP protein on its biosynthesis and stability. 
Information pertaining to this issue can be obtained in heterologous expression systems, 
which provide tools resulting in "in-vitro phenotypes". This approach was initially used to 
characterize seven BSEP mutations leading to severe BSEP deficiency syndrome. They were 
introduced into the corresponding conserved positions of rat Bsep with subsequent expression 
of these constructs in MDCK cells (47). Five of the studied mutations prevented the Bsep 
protein to be targeted to the apical membrane and/or showed blunted transport activity. 
Interestingly, the D482G mutation was found to exhibit decreased transport activity in this 
study, but after being cloned into mouse Bsep displayed normal function (48). This 
discrepancy could be due to species differences of the Bsep backbone. In light of the recent 
findings (16), the divergence could also relate to different mRNA stability. Other in vitro 
phenotyping studies with different BSEP mutants demonstrated not only alterations in BSEP 
targeting (15, 49), a shortening of the half life of BSEP in the plasma membrane (15) (see 
table 1) but also differences in ubiquitin dependent BSEP turnover (50). Lately, it was 
observed that the severity of BSEP deficiency syndrome phenotype correlates with membrane 
expression and protein stability of the BSEP mutants (51, 52). Interestingly, it was 
demonstrated that levels of the E297G and the D482G mutants of BSEP could be increased at 
the plasma membrane, if cells were treated with 4-phenylbutyrate (53). This may be 
therapeutically relevant, as both mutants display residual transport activity. As additional 
factors relevant for cell surface targeting of rat Bsep, accessory proteins (54, 55) and proper 
glycosylation of Bsep (56) have been identified. 
 
Regulation of BSEP expression and function 
The activity of the BSEP gene is predominantly controlled by the nuclear farnesoid X receptor 
(FXR) (2, 6, 46, 57-59). Bile acids are ligands of FXR, which is the main bile salt sensor 
within hepatocytes. Consequently FXR regulates bile salt levels in hepatocytes by suppressing 
the gene encoding the sodium-taurocholate uptake system, bile salt biosynthesis and last but 
not least activating the BSEP gene (46, 59, 60). As BSEP constitutes the rate-limiting step of 
transcellular transport of bile salts across hepatocytes, this later step is critical not only for 
bile formation but also for keeping the intracellular concentration of the potentially cytotoxic 
bile salts low. Hence, in many forms of liver disease, expression of BSEP is maintained, if not 
induced (reviewed in (57)). Therefore, FXR is a potential drug target for treatment of 
cholestatic liver disease (57, 61). FXR regulates the expression of target genes by binding as a 
heterodimer together with the retinoid X receptor RXRα. RXRα is activated by the vitamin A 
derivative 9-cis retinoic acid. In a recent study cholate feeding of mice with vitamin A 
deficiency resulted in a marked induction of Bsep expression at the mRNA and protein level 
(62), indicating a more complex regulation of BSEP transcription. Such a complexity is 
underscored by in vitro studies of the human promoter of BSEP demonstrating that vitamin 
D3 activated vitamin D receptor and repressed BSEP promoter driven reporter gene activity 
(63). It was also observed that liver receptor homolog 1 transcriptionally regulates the BSEP 
promoter (64). In a patient study, four heterozyogous variants of the FXR gene were identified 
in a cohort of women with intrahepatic cholestasis of pregnancy (65). In vitro testing of these 
variants revealed reduced translational activity of the variant genes leading to a reduced 
transactivation of a FXR-dependent promoter construct. Another clinical study observed in 
individuals, which were treated for three weeks with the weak FXR agonist (66) 
ursodeoxycholate an upregulation of BSEP protein in liver biopsies taken at the end of the 
treatment period (67). And finally, the canalicular transporter ATP8B1 (or FIC1), which is 
defective in patients with Byler’s disease activates in UPS cells the activity of the promoter 
for BSEP in parallel with a upregulation of FXR (68). This stimulation of the BSEP promoter 
is absent if mutants of ATP8B1 identified in Byler’s disease patients are expressed in the UPS 
cell system. Taken together, these findings demonstrate that regulation of BSEP expression is 
governed by a complex network of stimuli acting directly and indirectly on the promoter of 
BSEP. 
 
Animal models of liver disease have revealed considerable evidence for posttranslational 
regulation of Bsep, particularly by regulating the number of Bsep transporters in the 
canalicular membrane (reviewed in (8)). Cholestatic liver disease is frequently treated with 
ursodeoxycholate (69). In model systems, ursodeoxcholate acts by stimulating canalicular bile 
formation, which involves, among other transporters, the insertion of Bsep from an 
intracellular pool into the canalicular membrane (69, 70). This anticholestatic effect is 
mediated by a cooperative action of protein kinases C alpha and A (71). Recent studies have 
presented evidence for the presence of distinct microdomains in the canalicular plasma 
membrane of rat hepatocytes (72-74). These microdomains are characterized by a high 
cholesterol and sphingolipid content. ABC transporters including Bsep were found to partition 
into caveolin-1 enriched microdomains (74). Whether such microdomains are involved in 
regulation of the activity of Bsep and other canalicualar transporters remains to be elucidated. 
 
Conclusion and Outlook 
Evidence suggests that mouse, rat and human Bsep isoforms have similar kinetic parameters 
(25). This indicates that findings obtained in rodents can be extrapolated to the human 
situation. Studies on the inhibition of human and rodent BSEP/Bsep by drugs have indeed 
shown inhibition by cyclosporine and bosentan (24-27, 75). This approach should be used 
cautiously however, since the substrate specificity of rat and human BSEP/Bsep is not 
identical (76). For example, while taurolithosulfocholate is not transported by rat Bsep (24, 
76), it is a substrate of human BSEP (76). Furthermore, mice with an ablated Bsep gene do 
not develop severe cholestasis on a normal diet (77), but need to be put on a high cholate diet 
(78). As a consequence of absent Bsep, novel, more hydrophilic bile salts have been detected 
in the bile of knockout animals (77) as well as an upregulation of p-glyocoprotein, which 
could provide a salvage pathway for bile salts (79). Nevertheless, Bsep knockout mice can be 
used to develop novel therapeutic approaches, such transplantation of cells to correct 
consequences of non-functional BSEP (80). 
 
A first report on quantitative structure-activity relationship of inhibitors of BSEP has been 
published (81). Hence, it can be expected that more information on the structural 
requirements of BSEP inhibitors will become available. Such information undoubtedly will be 
highly valuable in the process of drug development for predicting potential BSEP inhibition. 
Certainly, knowledge on the atomic structure of BSEP will greatly enhance such predictions. 
Unfortunately, high resolution structural information of mammalian ABC-transporters 
including BSEP remains elusive (82). 
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